IDH1 and central nervous system cancer: Therefore, IDH1-mutant gliomas demonstrate a high level of oncometabolite D-2-hydroxyglutarate, which causes an increase in migration activity through the PI3K/AKT/mTOR pathway and morphology changes [19,20].